Umbralisib

Ukoniq (umbralisib) is a small molecule pharmaceutical. Umbralisib was first approved as Ukoniq on 2021-02-05. It is used to treat b-cell lymphoma marginal zone and follicular lymphoma in the USA. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. In addition, it is known to target casein kinase I isoform epsilon. Ukoniq's patents are valid until 2035-05-26 (FDA).